Helix BioPharma Corp.: Helix Biopharma Corp. Announces Fiscal 2021 First Quarter Results
Helix or the
Company ), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced its fiscal 2021 first quarter results for the period ending October 31, 2020.
OVERVIEW
The Company reported a net loss and total comprehensive loss of $222,000 for the three-month period ended October 31, 2020 (2019 - $2,214,000). Net loss and comprehensive loss for the three-month period ending October 31, 2020 included a gain from loss of control in Helix Immuno-Oncology S.A. ( HIO ) of $2,162,000 (2019 - $nil) on September 3, 2020.
On November 9, 2020, the Company announced that it has signed a definitive share purchase agreement with CAIAC Fund Management AG ( CAIAC ) to purchase the Company s remaining 29.89% holdings in Helix Immuno-Oncology S.A. ( HIO ), for gross proceeds of PLN 6,700,0
Forward-Looking Statements and Risks and Uncertainties
This news release contains forward-looking statements and information (collectively, forward-looking statements ) within the meaning of applicable Canadian securities laws. Forward-looking statements are statements and information that are not historical facts but instead include financial projections and estimates, statements regarding plans, goals, objectives, intentions and expectations with respect to the Company s future business, operations, research and development, including the Company s activities relating to DOS47, and other information in future periods.
Forward-looking statements include, without limitation, statements concerning (i) the Company s ability to operate on a going concern being dependent mainly on obtaining additional financing; (ii) the Company s priority continuing to be L-DOS47; (iii) the Company s development programs for DOS47, L-DOS47, V-DOS47 and CAR-T; (iv) future expenditures, the insufficien